Dental Bone Graft and Substitutes Market Analysis & Forecast: 2026-2033
The Dental Bone Graft and Substitutes Market size is anticipated to grow at a CAGR of 7.2% with USD 1,500 Mn in 2026 and is expected to reach USD 2,440 Mn in 2033. The primary drivers are defined by rising demand for implant dentistry, periodontal reconstruction, ridge augmentation, and socket preservation across dental clinics, hospitals, and ambulatory surgical centers. Some of the other factors include increasing tooth loss, cosmetic dentistry adoption, biomaterial innovation, and preference for synthetic and xenograft substitutes. The WHO reported in March 2025 that the oral diseases affect nearly 3.7 billion people globally, thereby supporting the demand for dental grafting solutions.
On the basis of product type, the xenograft segment is projected to account for the largest Dental Bone Graft and Substitutes Market share of 38.5% in 2026. The segment’s growth is owing to their extensive clinical evaluation and established osteoconductive performance.
Multiple ongoing and completed clinical studies registered on ClinicalTrials.gov are actively assessing bovine‑derived and porcine‑derived xenografts for alveolar ridge preservation, sinus augmentation, and socket preservation, indicating sustained research investment in this material class.
According to WHO oral health data, 350, creating significant indications for bone graft intervention prior to implant placement.
A notable clinical development in 2026 includes completion of enrollment in the Phase I/II RESTORE study (Theradaptive’s OsteoAdapt DE) comparing novel regenerative approaches against standard xenograft bone grafts in alveolar ridge augmentation, underscoring xenografts as the control standard in cutting
To learn more about this report, Request Free Sample
On the basis of basis of material type, the animal source segment lead with a major 42.1% share in 2026. The growth is owing to the broad clinical use of xenografts, mainly bovine- and porcine-derived graft materials, in periodontal defect repair, alveolar ridge preservation, sinus augmentation, and implant-site development.
The demand is increasing with the rising volume of dental implant procedures, as the FDA notes that up to 50% of dental implant procedures may require bone graft support. The animal-derived grafts are extensively preferred because they offer an osteoconductive scaffold which supports the bone regeneration before or during implant placement. The bovine-derived Bio-Oss is among the commonly used dental bone graft materials.
The regulatory clarity is also improved with the FDA’s August 2025 finalized guidance on animal studies for dental bone grafting material 510(k) submissions, thereby strengthening the consistent review of animal-derived devices. The clinical activity also continues through the U.S.-registered trials comparing collagen-enriched bovine xenografts with allografts.
In the United States, the dental bone graft and substitutes segment is growing at a rapid pace. This is because the dental implants and periodontal treatments are becoming more widely adopted. These grafting materials are used to fill and reconstruct periodontal and alveolar defects before implant placement, in accordance with the 21 CFR § 872.3930 requirements.
The growth is also owing to the regulatory clarity. The updated FDA guidance finalized in August 2025 clarifies animal The expansion in clinical research also reflects the rising demand. The active trials on ClinicalTrials.gov are investigating autogenous tooth bone grafts for ridge preservation and are also comparing allografts versus xenografts for alveolar augmentation.
In January 2026, Alphatec Holdings, a leader in spine surgery solutions, teamed up with Theradaptive, a clinical-stage regenerative medicine firm. Under the agreement, Alphatec secures exclusive U.S. rights to Theradaptive’s OsteoAdapt osteoinductive bone graft.
The 3D‑printed synthetics segment of the dental bone graft and substitutes market is expanding rapidly due to technological innovation and regulatory progress.
In Nov 2023, CMFlex, a customizable 3D‑printed synthetic graft developed by Dimension Inx and manufactured on Desktop Health’s 3D‑Bioplotter, received FDA clearance and has been applied in dental socket preservation and jaw defect cases, demonstrating the clinical feasibility of patient-specific synthetic grafts.
Further, in February 2026, Biomendex Oy secured FDA 510(k) clearance for Adaptos Fuse. This allows for its U.S. market launch for dental and craniofacial bone reconstruction, thereby expanding the availability of the off-the-shelf synthetic alternatives.
The government health data indicates the increasing dental implant procedures, rising from 1% in 2009 to 2% in 2023 among adults, thereby propelling the higher adoption of synthetic grafts. These technological innovations, regulatory approvals, as well as the rising procedural demand are fueling strong growth for 3D‑printed synthetics in dental bone grafting.
|
Current Event |
Description and its Impact |
|
WHO Guidance on Biocompatible Bone Graft Materials |
|
|
U.S. FDA Clearance for Bone Graft Substitutes |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 42.8% of the market share in 2026. The region’s growth is owing to a large treated population base for periodontal bone loss, tooth extraction, ridge preservation, and implant-preparation procedures.
In the U.S., NIDCR reports that 42.2% of adults aged 30 years and above had total periodontitis, including 7.8% with severe disease, creating sustained need for regenerative NIDCR also reports that 17.3% of seniors aged 65 years and older have no remaining teeth, supporting demand for implant-supported rehabilitation where bone grafting is often required to rebuild or preserve jawbone volume.
Regulatory activity has further supported the availability of products in the bone graft and substitutes market. In February 2025, the U.S. FDA granted 510(k) clearance (K241186) for a Synthetic Bone Graft Particulate, which is specifically intended to augment alveolar bone in tooth extraction sites and facilitate subsequent implant or restorative procedures.
Asia Pacific is expected to witness strong growth in Dental Bone Graft and Substitutes Market over the forecast period. The region’s growth is owing to the prevalence of dental conditions requiring bone regeneration rises across the region. Oral diseases such as tooth caries and periodontal bone loss are key drivers of demand for graft and substitute products.
According to the World Health Organization (WHO), in the SouthIn the broader Asia region, research based on the Global Burden of Disease 2021 database reported that there were approximately 684.7 million people with periodontal diseases, a leading indication for bone grafts and alveolar augmentation procedures.
The growing implant‑based rehabilitation efforts and governmental emphasis on integrating oral health into universal health coverage are also supporting the demand for bone graft and substitute products. A recent clinical development is ClinicalTrials.gov ID NCT07362394, a study initiated in 2026 by the National University of Malaysia comparing autologous dentin graft versus xenograft in periodontal bone defect repair, thereby indicating active research and adoption of novel graft technologies.
The U.S. market is expanding as tooth loss, periodontal bone damage, and implant-based rehabilitation propel demand for alveolar ridge preservation and grafting.
According to the CDC 2024 Oral Health Surveillance Report, the adults aged 65 and older have an average 6.4 missing teeth due to disease, thereby emphasizing the demand for ridge preservation and regenerative treatments.
In February 2025, the FDA cleared Synthetic Bone Graft Particulate, a 45S5 bioactive-glass absorbable graft from and thereby strengthening the growth and adoption in American dental surgeries.
In China, the rising demand for dental implants and periodontal treatments is propelling the growth in the dental bone graft and substitutes market. This is supported by government incentives for innovative regenerative devices.
The dental bone graft substitutes in China are regulated as medical devices under the National Medical Products Administration (NMPA), thus requiring Class II/III registration with clinical evidence. In June 2023, the NMPA received 466 applications under innovation and priority review procedures, thereby reflecting a growing focus on advanced graft materials.
A notable development includes Regenity receiving NMPA approval for MatrixOss porcine bone mineral in March 2024 for GTR/GBR, thereby broadening treatment options and encouraging the market expansion.
Some of the major key players in Dental Bone Graft and Substitutes Market are Institut Straumann AG, Geistlich, DENTSPLY International, Zimmer Biomet, Medtronic Plc., BioHorizons IPH, Inc., ACE Surgical Supply Company, Inc., RTI Surgical, Inc., LifeNet Health, and Citagenix.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,500 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.2% | 2033 Value Projection: | USD 2,440 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Institut Straumann AG, Geistlich, DENTSPLY International, Zimmer Biomet, Medtronic Plc., BioHorizons IPH, Inc., ACE Surgical Supply Company, Inc., RTI Surgical, Inc., LifeNet Health, and Citagenix |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
